Please review our updated Billing Policy; click here.

Our News

New HematoLogics Publication showing the integrated analysis of genotype and phenotype revealing the clonal evolution and cytogenetically driven disruption of myeloid cell maturation and myelodysplastic syndromes.

New HematoLogics Publication outlining the instrumental use of FACS FISH for the detection of BCR/ABL-1 positive T-cell lymphoblastic leukemia arising in early lymphoid progenitor cells and possible treatment implications.

New Test Announcement: CD33, a biomarker that determines response to Mylotarg™ therapy is now available at HematoLogics.

HematoLogics in conjunction with Children’s Oncology Group discovered a new phenotype of Acute Myeloid Leukemia called RAM.

HematoLogics is the recognized leader for Measurable Residual Disease testing for Acute Leukemia.

HematoLogics has increased the specificity of MYD88 L265P by 33% and the sensitivity of CXCR4 by 63% through Flow Cytometric Cell Sorting of Plasma and Lymphoid cells.

Our Expertise

Residual Disease

Small numbers of residual malignant cells are associated with clinical relapse at a later date. HematoLogics is the leader in residual disease testing by flow cytometry using a Difference from normal approach. We also offer a comprehensive menu of quantitative PCR assays for translocations, flow cytometric cell sorting and molecular profiling by DNA analysis.

Cytopenias  /MDS

HematoLogics has found that 30% of all cytopenias are associated with abnormal myeloid cells. With our unique  Flow Cytometric analysis, we use  ∆N: (Difference from Normal) Flow Cytometry and assign an MDS Flow score that is associated with Myelodysplastic syndromes. We also offer aCGH/SNP microarray (LOH), FISH panels, cytogenetic karyotypes,  comprehensive DNA mutation panels, and Next Generation Sequencing.

Plasma Cells

HematoLogics combines plasma cell enrichment and plasma cell sorting for FISH and aCGH/SNP microarray analysis for the diagnosis, prognosis, and monitoring of plasma cell neoplasms. For patients with concurrent monoclonal B-cell and plasma cell populations, we offer PCR IGH monoclonality profiling and MYD88 on the sorted populations to establish the diagnosis.


HematoLogics has extensive experience analyzing biopsies from patients on clinical trials, including those treated with novel therapies. Please contact us to find out more about how we can help clinical trial monitoring or assessment of new drug targets for the treatment of myeloid or lymphoid neoplasms.

Who We Are

HematoLogics has assembled an in-house group of experts in each diagnostic field so that all testing is performed at HematoLogics and not sent out to other specialty labs.

This speeds up analysis and permits rapid response to unexpected findings due to communication between directors on every case.

What We Do

HematoLogics provides immunophenotyping, cytogenetics, fluorescence in situ hybridization, molecular analysis studies, next-generation sequencing, and our own state-of-the-art ∆N: (Difference from Normal) Flow Cytometry

Send us a sample, and we will provide full interpretive reports.

Come Visit HematoLogics